title: Peroxisome proliferator-activated receptor (PPAR) agonists as promising new medications for drug addiction: preclinical evidence.
abstract: This review examines the growing literature on the role of peroxisome proliferator-activated receptors (PPARs) in addiction. There are two subtypes of PPAR receptors that have been studied in addiction: PPAR-α and PPAR-γ. The role of each PPAR subtype in common models of addictive behavior, mainly pre-clinical models, is summarized. In particular, studies are reviewed that investigated the effects of PPAR-α agonists on relapse, sensitization, conditioned place preference, withdrawal and drug intake, and effects of PPAR-γ agonists on relapse, withdrawal and drug intake. Finally, studies that investigated the effects of PPAR agonists on neural pathways of addiction are reviewed. Taken together these preclinical data indicate that PPAR agonists are promising new medications for drug addiction treatment.
authors.affiliation: Translational Addiction Research Laboratory, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. bernard.lefoll@camh.ca
authors.forename: Bernard
authors.initials: B
authors.lastname: Le Foll
authors.forename: Patricia
authors.initials: P
authors.lastname: Di Ciano
authors.forename: Leigh V
authors.initials: LV
authors.lastname: Panlilio
authors.forename: Steven R
authors.initials: SR
authors.lastname: Goldberg
authors.forename: Roberto
authors.initials: R
authors.lastname: Ciccocioppo
mesh_terms: D000818:Animals; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006801:Humans; D047493:PPAR alpha / Q000819:agonists* / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D055502:Secondary Prevention; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy / Q000503:physiopathology; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D047493:PPAR alpha; D047495:PPAR gamma